Tag: Pharmaceuticals
When Does Interpretation Become Rewriting? The FTC Runs With the Actavis...
Kent Bernard, Sep 30, 2013
A Hatch-Waxman settlement case finally reached the Supreme Court, and when it did the Court in FTC v. Actavis rejected both...
Bid Rigging In Public Procurement Of Generic Drugs In Mexico
Ernesto Estrada, Samuel Vazquez, Jul 28, 2013
This document studies bid rigging in public procurement of generic drugs in Mexico. The study is based on...
Where Is the Italian Supreme Administrative Court Going in the Never-Ending...
Daniela Ampollini, Jul 15, 2013
It is obvious to all that know even a little of patent law, that the validity (and, even before, the...
Generic Drugmakers Will Challenge Patents Even When They Have a 97%...
Jonathan Gleklen, Kelly Smith, Sep 13, 2012
A striking aspect of the Third Circuit's decision on Hatch-Waxman patent settlements in the K-Dur litigation is the panel's...
From Astra-Zeneca to Pfizer: When Protection of Originators Patents Ceases to...
Stefano Grassani, Jul 27, 2012
On Jan. 11, 2012, the Italian Antitrust Authority ("IAA") found Pfizer Inc. and its Swedish and Italian subsidiaries guilty of...
Looking for Sense in the Italian Antitrust Authority Decision in the...
Daniela Ampollini, Jul 27, 2012
The January 2012 decision of the Italian Antitrust Authority ("IAA") in the Pfizer case, involving Pfizer's actions to counter the marketing...
Cervantes Sequel: The FTC’s Quest to End Pay-for-Delay Pharma Settlements
Anne Layne-Farrar, Jun 27, 2012
We are drawing close to the thirtieth anniversary of the Drug Price Competition and Patent Term Restoration Act, better known...
Reverse Payment Settlements: Presumptively Bad or Usually Acceptable?
Kyle Musgrove, Richard Ripley, Jun 27, 2012
In April 2012, the Federal Trade Commission ("FTC") suffered yet another rebuke of what FTC Chair Jon Leibowitz...
Federal Trade Commission Rejected in “Reverse Payment” Suit
Kevin Noonan, Jun 27, 2012
The Federal Trade Commission in recent years has identified a practice it considers to be a threat to consumers regarding...
Eleventh Circuit Rejects the Strength of a Patent as a Criterion...
Jodi Lucena-Pichardo, William Rooney, Jun 27, 2012
The Eleventh Circuit's recent decision in Federal Trade Commission v. Watson Pharmaceuticals, Inc. (the "AndroGel" decision) addresses the latest...
